Department of Hematology and Oncological Sciences L.A.Seragnoli, S.Orsola-Malpighi Hospital, University of Bologna, Italy.
J Transl Med. 2010 Nov 15;8:117. doi: 10.1186/1479-5876-8-117.
Recent years have seen a growing interest in insulin-like growth factor 1 receptor (IGF1R) in medical oncology. Interesting data have been reported also on IGF1r in gastrointestinal stromal tumors (GISTs) especially in children and in young adult patients whose disease does not harbour mutations on KIT and PDGFRA and are poorly responsive to conventional therapies. However, it is too early to reach conclusions on IGF1R as a novel therapeutic target in GIST because the receptor's biological role is still to be defined and the clinical significance in patients needs to be studied in larger studies. We update and comment the current literature on IGF1R in GISTs and discuss the future perspectives in this promising field.
近年来，医学肿瘤学领域对胰岛素样生长因子 1 受体 (IGF1R) 的兴趣日益浓厚。有趣的数据也已经在胃肠道间质瘤（GIST）中报告，尤其是在儿童和年轻成年患者中，这些患者的疾病没有 KIT 和 PDGFRA 突变，对常规治疗反应不佳。然而，对于 IGF1R 作为 GIST 的一个新的治疗靶点，现在下结论还为时过早，因为受体的生物学作用仍有待确定，并且在患者中的临床意义需要在更大的研究中进行研究。我们更新并评论了目前关于 GIST 中 IGF1R 的文献，并讨论了这个有前途的领域的未来前景。
